Insulin Delivery Device Market

• Tandem Diabetes Care, Inc. (USA) announced an agreement to develop and commercialize integrated diabetes solutions combining Abbott’s (US) future dual glucose-ketone sensor with Tandem’s insulin delivery systems. The collaboration aimed to help individuals manage diabetes more effectively by detecting early rises in ketones, thereby preventing diabetic ketoacidosis. (June 10, 2025)
• Medtronic plc (Ireland) announced that the U.S. FDA approved the Simplera Sync™ sensor for use with the MiniMed™ 780G system. This approval expanded Medtronic’s CGM portfolio, providing users with more flexibility in managing their diabetes. (April 18, 2025)

Drivers: Rising global prevalence of diabetes

The primary driver for the insulin delivery device market is the rising global prevalence of diabetes. According to the International Diabetes Federation (IDF), approximately 588.7 million people were living with diabetes in 2024, a figure projected to rise to 852.5 million by 2050. This alarming increase is largely attributed to lifestyle factors such as obesity, sedentary behavior, and unhealthy diets. In response, healthcare systems worldwide are prioritizing diabetes management, leading to a surge in demand for effective insulin delivery solutions.

Companies like Medtronic and Novo Nordisk are at the forefront of this market, continuously innovating to meet the growing needs of diabetic patients. For instance, Medtronic’s MiniMed™ 780G system, which integrates advanced algorithms for insulin delivery, exemplifies the technological advancements aimed at improving patient outcomes. Furthermore, government initiatives, such as the U.S. Centers for Disease Control and Prevention (CDC) programs promoting diabetes awareness and management, are enhancing access to insulin delivery devices. This combination of rising diabetes rates and supportive healthcare policies is driving significant growth in the insulin delivery device market.

Opportunities: Increasing healthcare expenditure on diabetes care

A significant opportunity in the insulin delivery device market lies in the increasing healthcare expenditure on diabetes care. The global health spending associated with diabetes reached USD 1.015 trillion in 2024, reflecting a 338% increase over the past 17 years. This surge in spending is indicative of a broader recognition of the importance of effective diabetes management and the need for advanced treatment options.

Companies are capitalizing on this trend by developing innovative insulin delivery devices that integrate smart technology. For example, Insulet Corporation has introduced the Omnipod 5, an automated insulin delivery system that enhances patient convenience and adherence. Additionally, government initiatives aimed at improving access to diabetes care, such as subsidies for insulin delivery devices in countries like Canada, are further expanding market opportunities. As healthcare systems increasingly prioritize preventive care and chronic disease management, the insulin delivery device market is well-positioned to benefit from these trends, leading to enhanced patient outcomes and reduced long-term healthcare costs.

Challenges: High costs associated with advanced devices

Despite the growth potential, the insulin delivery device market faces significant challenges, particularly concerning the high costs associated with advanced devices. For instance, the average price of insulin pumps can range from USD 6,000 to USD 8,000, which can be prohibitive for many patients, especially in low- and middle-income countries. This financial barrier limits access to essential diabetes management tools, exacerbating health disparities.

Moreover, the high out-of-pocket expenses for insulin delivery devices in developing regions hinder widespread adoption. According to the IDF, the cost of diabetes care can be a substantial burden, with many patients unable to afford necessary treatments. Additionally, regulatory hurdles related to device approval and safety standards can delay the introduction of new technologies, further complicating market dynamics. Companies like Eli Lilly and Sanofi are working to address these challenges by developing more affordable solutions and advocating for better insurance coverage. However, until these issues are resolved, the market’s growth may be constrained, limiting the potential benefits of innovative insulin delivery technologies for patients worldwide.

The global insulin delivery devices market is a vital segment within the healthcare industry, focusing on the development and distribution of devices that facilitate insulin administration for diabetes management. Valued at USD 31.5 billion in 2024, the market is projected to grow significantly, reaching around USD 51.6 billion by 2030, reflecting a CAGR of 8.6 % during this period.

This growth is primarily driven by the increasing prevalence of diabetes worldwide, which is exacerbated by lifestyle changes and an aging population. The demand for innovative insulin delivery solutions is rising, particularly as patients seek more convenient and effective ways to manage their condition. Key advancements include the integration of smart technology into insulin delivery devices, such as automated insulin delivery systems (AID) that utilize continuous glucose monitoring (CGM) data to optimize insulin dosing. These innovations not only enhance patient adherence but also improve overall glycaemic control.